ValuEngine cut shares of Immunic (NASDAQ:IMUX) from a buy rating to a hold rating in a research report sent to investors on Monday morning, ValuEngine reports.

Other equities analysts also recently issued reports about the company. Zacks Investment Research downgraded Immunic from a hold rating to a sell rating in a research report on Tuesday, September 10th. Chardan Capital set a $40.00 target price on shares of Immunic and gave the stock a buy rating in a research note on Friday, September 6th.

Shares of NASDAQ IMUX opened at $14.37 on Monday. The stock has a market capitalization of $15.33 million, a price-to-earnings ratio of -0.40 and a beta of 3.59. The company has a 50 day moving average price of $14.07. Immunic has a 52-week low of $6.00 and a 52-week high of $46.80.

Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.80). As a group, equities research analysts predict that Immunic will post -3.25 EPS for the current year.

A number of institutional investors have recently bought and sold shares of IMUX. Omega Fund Management LLC acquired a new stake in Immunic in the 2nd quarter valued at approximately $15,731,000. Independent Advisor Alliance purchased a new position in Immunic in the 2nd quarter valued at approximately $804,000. BlackRock Inc. purchased a new stake in shares of Immunic during the 2nd quarter worth $145,000. Vanguard Group Inc. purchased a new stake in shares of Immunic during the 2nd quarter worth $132,000. Finally, Tower Research Capital LLC TRC purchased a new stake in shares of Immunic during the 2nd quarter worth $33,000.

About Immunic

Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.

Recommended Story: What is dividend yield?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.